Art. 4 Ordinance of September 21, 2018, on Medicinal Products (OMed) - Risk Management Plan
Art. 4 OMéd · Risk Management Plan
A risk management plan must be attached to: a. applications for marketing authorization of a human medicinal product containing at least one new active substance, according to the procedure specified in Art. 11 of the Therapeutic Products Act (ordinary procedure); b. applications for marketing authorization of an important medicinal product for treating rare diseases (orphan drug) containing at least one new active substance; c. applications for marketing authorization of a new indication for a medicinal product referred to in let. a or b that is already authorized.
It includes a risk assessment and a pharmacovigilance plan.
The pharmacovigilance plan outlines how the risks related to the use of the medicinal product are systematically cataloged and identified, as well as the planned prevention measures (Art. 11, para. 2, let. a, subpara. 5, of the Therapeutic Products Act).